Google
IMTX — IMMATICS NV (Healthcare >> Biotechnology)
IMTX FAQ
What is IMTX's ROE?
IMMATICS NV reports a Return on Equity (ROE) of -46.99%.
What is IMTX's dividend yield?
IMMATICS NV offers a dividend yield of 0.00%.
What is IMTX's Deepscope Quality Score?
Deepscope rates IMTX's overall financial quality at 0 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy IMTX?
Deepscope's AI Timing Score for IMTX is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does IMTX belong to?
IMMATICS NV is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 9.79
Price
-0.39
(-3.83%)
Day Change
|
|
|---|
IMTX, ファンダメンタルスコアはnot good ( ファンダメンタル = 0) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 71 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 9.79 |
| PBV / Sector |
3.05 / 4.63
|
| Earning Per Share | -1.51 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
6.50 M
|
| Average 1W Daily Value |
9.63 M
|
| Timing Factors |
|
14% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:08:46 |
| Symbol | IMTX |
| Name | IMMATICS NV |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 136.67 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,391.33 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Paul-Ehrlich-Strasse 15-19, Tübingen, Germany, 72076
Phone: 49 7071 5397 0
Website: https://www.immatics.com
Employees: 589
Sector: Healthcare >> Biotechnology
Description: Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
